Management

NIT is led by a highly experienced team of scientists, clinicians and strategists, relentlessly pursuing the development of novel cancer and immune therapies to bring better treatment options to patients.

Se Hwan Yang, Ph.D. – Chief Executive Officer

Dr. Se Hwan Yang founded NeoImmuneTech in January 2014. Dr. Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and Hyleukin-7 drug candidate. Prior to his position at NIT, Dr. Yang was Genexine’s Head of Research Institute and Business division from 2007 to 2014 and has served as a BOD member of Genexine. He received his Ph.D. from Pohang University of Science and Technology and has over 20 years of experiences of research, product development and business in life sciences, including molecular biology, immunology and protein engineering.

Richard Kang, Ph.D. – Chief Operating Officer / Chief Financial Officer

Dr. Richard Kang has served as Chief Operating Officer and Chief Financial Officer since 2015 and 2018, respectively. Dr. Kang joined NeoImmuneTech’s Board of Directors in January 2014. Dr. Kang is an active serial entrepreneur. He has served as Board of Directors and Chief Operating Officer at NeuroBo Pharmaceuticals, Inc. and has served as Board of Directors and Chief Executive Officer at JK BioPharma Solutions, Inc. Prior to diving in Bio/Pharmaceutical industry, he had been achieved scientific publications including Cell and Nature as a scientist in Genetics, Molecular and Cellular Biology and Pathology. Dr. Kang holds B.S. and M.S. from Seoul National University in Korea and Ph.D. from the University of Edinburgh in UK and was a postdoctoral visiting fellow at National Cancer Institute, NIH.

NgocDiep (“Diep”) Le, M.D., Ph.D. – Chief Medical Officer

Dr. Le joined NeoImmuneTech in October 2018 as the Chief Medical Officer (CMO). She is a trained medical oncologist with over 15 years of drug development experience across all phases of Oncology R&D, in both solid tumors and hematologic malignancies. Most recently, she served as the CMO at Verastem where she led the company’s first NDA submission and successful approval of COPIKTRATM in multiple indications. Prior to Verastem, she was the Vice President in Immuno-Oncology Innovative Medicines at MedImmune, served as Global Clinical Program Head at Novartis Oncology, and Executive Medical Director at GSK where she successfully led the clinical development program for the MEK inhibitor trametinib (MEKINISTTM) from the first-in-human study through FDA approval. Dr. Le began her industry career at Amgen, Inc. as Medical Sciences Medical Director in Early Development Oncology. She received her B.S. in Biology from the California Institute of Technology, earned her MD and PhD in Cancer Biology from Stanford University School of Medicine. She completed a Medical Oncology Fellowship at the Duke University Comprehensive Cancer Center and was a faculty member at Duke University prior to joining biopharmaceutical industry.

Jaehan Park – Chief Strategy Officer

Mr. Park joined NeoImmuneTech, Inc. in 2016 as Chief Strategy Officer, in charge of Strategy and Business Development. He has expertise in strategic planning and business development in the bio industry with 13+ years’ experience. Prior to joining NIT, Mr. Park served as Head of Business Development at Genexine. He began his professional career as a business consultant at Accenture, Ltd. Mr. Park received his B.S. degree in Physics from Seoul National University and Master of Engineering degree in Biotechnology from Yonsei University.